Recombinant human luteinising hormone: an effective new gonadotropin preparation

Hull, M. G. R.; Corrigan, Elizabeth; Piazzi, A.; Loumaye, Ernest

doi:10.1016/s0140-6736(94)91373-0

Cited by 58 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three (60%) of the 5 women conceived within 4 cycles of treatment with preparations containing both FSH and LH. One of these pregnancies was conceived during the first cycle of treatment with recombinant FSWLH and HCG (5).…”

Section: Resultsmentioning

confidence: 99%

Ovarian Response to Purified FSH in Infertile Women with Long‐standing Hypogonadotrophic Hypogonadism

Fox

Ekeroma

Wardle

1997

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

EDITORIAL COMMENT: We accepted this paper to illustrate an important point, namely that purified FSH preparations may not be appmpriate for ovulation induction in women lacking adequate levels of endogenous luteinizing hormone. Furthermore, if these preparations are used then reliance on oestradiol determinations alone m y lead to inappropriate conclusions about the number of preovulatory follicles. Howevel; there is pmbably a place for preparations of purified FSH in women with high cimulating levels of endogenous Iuteinizing hormone. Summary: It has previously been proposed that all anovulatory women requiring 1. Consuitant Senior Lecturer. 2. Gyna~cological Registrar. Address for comspondcnce: D r Robert Fox.

show abstract

Section: Resultsmentioning

confidence: 99%

Ovarian Response to Purified FSH in Infertile Women with Long‐standing Hypogonadotrophic Hypogonadism

Fox

Ekeroma

Wardle

1997

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…In the late 1990's, a different type of gonadotropin had been developed: using recombinant DNA technology, recombinant FSH (rFSH) was produced, obtaining preparations that have high purity and biological potency and are completely LH free [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation

Levi-Setti

Alviggi

Colombo

et al. 2014

J Endocrinol Invest

View full text Add to dashboard Cite

BackgroundGonadotropins are protein hormones which are central to the complex endocrine system that regulates normal growth, sexual development, and reproductive function. There is still a lively debate on which type of gonadotropin medication should be used, either human menopausal gonadotropin or recombinant follicle-stimulating hormone. The objective of the study was to perform a systematic review of the recent literature to compare recombinant follicle-stimulating hormone to human menopausal gonadotropin with the aim to assess any differences in terms of efficacy and to provide a cost evaluation based on findings of this systematic review.MethodsThe review was conducted selecting prospective, randomized, controlled trials comparing the two gonadotropin medications from a literature search of several databases. The outcome measure used to evaluate efficacy was the number of oocytes retrieved per cycle. In addition, a cost evaluation was performed based on retrieved efficacy data.ResultsThe number of oocytes retrieved appeared to be higher for human menopausal gonadotropin in only 2 studies while 10 out of 13 studies showed a higher mean number of oocytes retrieved per cycle for recombinant follicle-stimulating hormone. The results of the cost evaluation provided a similar cost per oocyte for both hormones.ConclusionsRecombinant follicle-stimulating hormone treatment resulted in a higher oocytes yield per cycle than human menopausal gonadotropin at similar cost per oocyte.

show abstract

“…FSH alone is insufficient for full follicular maturation and oocyte competence in the case of severe gonadotropin deficiency; nevertheless, using FSH alone has been demonstrated to be sufficient for ovarian stimulation in normogonadotropic women. 62 , 63 , 79 …”

Section: Stimulation Of Follicular Development With Rfsh and Rlh In Wmentioning

confidence: 99%

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency

Rinaldi¹,

Selman²

2016

IJWH

View full text Add to dashboard Cite

A severe gonadotropin deficiency together with chronic estradiol deficiency leading to amenorrhea characterizes patients suffering from hypogonadotropic hypogonadism. Administration of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to these patients has been shown to be essential in achieving successful stimulation of follicular development, ovulation, and rescue of fertility. In recent years, the availability of both recombinant FSH (rFSH) and recombinant LH (rLH) has provided a new therapeutic option for the stimulation of follicular growth in hypopituitary–hypogonadotropic women (World Health Organization Group I). In this article, we review the data reported in the literature to highlight the role and the efficacy of using recombinant gonadotropins, rFSH and rLH, in the treatment of women with severe LH/FSH deficiency. Although the studies on this issue are limited and the experiences available in the literature are few due to the small number of such patients, it is clearly evident that the recombinant gonadotropins rFSH and rLH are efficient in treating patients affected by hypogonadotropic hypogonadism. The results observed in the studies reported in this review suggest that recombinant gonadotropins are able to induce proper follicular growth, oocyte maturation, and eventually pregnancy in this group of women. Moreover, the clinical use of recombinant gonadotropins in this type of patients has given more insight into some endocrinological aspects of ovarian function that have not yet been fully understood.

show abstract

Recombinant human luteinising hormone: an effective new gonadotropin preparation

Cited by 58 publications

References 4 publications

Ovarian Response to Purified FSH in Infertile Women with Long‐standing Hypogonadotrophic Hypogonadism

Ovarian Response to Purified FSH in Infertile Women with Long‐standing Hypogonadotrophic Hypogonadism

Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency

Contact Info

Product

Resources

About